Table 2.

The Pharmacokinetics/Pharmacodynamics (PK/PD) parameter of AUC/MIC (the area under the concentration–time curve divided by the minimal inhibitory concentration) and the corresponding antimycoplasmal effect in various administration regimens of tilmicosin.

Dose (mg/kg)	Time (h)	E (ΔLog10CUF/g)	AUC/MIC (h)
1	0–24	0.74	150.81
	0–48	1.21	279.78
	0–72	1.44	367.62
2	0–24	0.90	476.49
	0–48	1.47	893.51
	0–72	1.84	1,173.78
4	0–24	0.97	603.54
	0–48	1.69	1,121.12
	0–72	2.02	1,472.38
7	0–24	1.01	1,298.28
	0–48	1.83	2,544.98
	0–72	2.38	3,410.21
10	0–24	1.32	2,418.24
	0–48	2.33	4,581.45
	0–72	3.19	6,033.34
15	0–24 h	1.87	3,573.65
	0–48	2.47	6,701.35
	0–72	3.68	8,803.37
30	0–24	2.06	7,307.02
	0–48	3.10	13,660.61
	0–72 h	3.94	17,923.84

E is the antibacterial effect that was assessed as the reduction in log₁₀ CFU/lung after each administration of tilmicosin, compared to the log₁₀ CFU/lung in untreated control group (absence of tilmicosin).